Handbook of Targeted Cancer Therapy and Immunotherapy : Breast Cancer / Senthil Damodaran and Debu Tripathy.

Format:

Book

Author/Creator:

Damodaran, Senthil, author.

Tripathy, Debu, author.

Language:

English

Subjects (All):

Cancer--Chemotherapy.

Cancer.

Drug targeting.

Cancer--Treatment.

Physical Description:

1 online resource (120 pages) : illustrations

Edition:

First edition.

Place of Publication:

Philadelphia, PA : Wolters Kluwer, [2023]

Summary:

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer provides a practical overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Drs. Senthil Damodaran and Debu Tripathy of MD Anderson Cancer Center helps you filter and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of approved or investigational targeted agents and combinations of agents.

Contents:

Intro

Title Page

Copyright Page

Contributors

Preface

Acknowledgments

Contents

SECTION 1: Targets of Interest in Breast Cancer

CHAPTER 1: Androgen Receptor

CHAPTER 2: BRCA1/2

CHAPTER 3: ESR1

CHAPTER 4: PIK3CA

CHAPTER 5: HER2 (ERBB2) Mutations

CHAPTER 6: Akt1 and PTEN

CHAPTER 7: FGFR

CHAPTER 8: NTRK

CHAPTER 9: HER2 Amplifications

CHAPTER 10: PD-1/PD-L1/MSI/TMB

CHAPTER 11: TROP-2

SECTION 2: Molecular Diagnostics and Testing

Molecular Diagnostics for Breast Cancer

Molecular Testing Platforms

Sample Testing

Actionable Genetic Alterations and Pathways in Breast Cancer

NGS Assays for Clinical Practice

FoundationOne CDx

Guardant360

MSK-IMPACT

CARIS

Tempus

Germline Variant Identification on Somatic NGS Panel

Somatic and Germline Variant Identification

SECTION 3: Molecular Targets and Pathways

An Introduction to the Organization of Cancer Cell Signaling

Signal Transduction Roadmap

VEGF and VEGFR

FGF and FGFR

PDGF and PDGFR

Angiopoietin and TIE Receptors

IGFR and Insulin Receptors

Targeting IGFR and Insulin Receptors

TGFT/SMAD

EGFR

EGFR Signaling

HER2 (Also Known as ERBB2)

MET (Also Known as HGF Receptor)

RET Receptor

ALK Receptor

KIT Receptor

ROS Receptor

Receptor Tyrosine Kinases (Activation Cascade)

Cell Signaling Pathways

Rapamycin and Its Mammalian Target (mTOR)

PI3K-AKT-mTOR Pathway

PI3K, AKT, PTEN, TSC in Cancer

mTORC1,2

NF-Kappa B-Master Immune Regulator

NF- B Pathway

G-Protein-Coupled Receptors

Mitogen-Activated Protein Kinase (MAPK)

RAS/MAPK Pathway

Targeting BRAF/MEK

Rous Sarcoma Virus Oncogene (SRC)

SRC Pathway

β-Catenin-Cell Adhesion

Wnt Pathway

Fruit Fly Mutations and Related Genes

Hedgehog Pathway

NOTCH Pathway.

B-Cell Lymphoma 2 (BCL-2)/Cysteine Aspartates (CASPASES)

Janus Kinase and Signal Transducer and Transcription

JAK/STAT Pathway

Apoptosis (Greek-"Leaves Falling from a Tree")

Death Receptors (DRs) and Apoptosis

Nuclear Factors and DNA Repair

TP53: Master Cell Cycle Regulator

Cell Regulation by RB1, CDKs

DNA Damage Response

Aurora Kinase

Overview of Angiogenic Signaling

Angiogenesis: A Hallmark of Cancer

Angiogenesis Regulators

Immunotherapy

Management of Immune-Related Adverse Events (irAEs)

Epigenetics

Targeting Epigenetics

Antibody Drug Conjugates (ADCs) Have Variable "­Payloads" and Multiple Microenvironmental Targets

Tropomyosin-Related Kinases

Metabolism: Glycolysis and the TCA Cycle

Targeting Cancer Metabolism

Ewing Sarcoma Gene Fusion

SECTION 4: Targeted and Immunotherapy Agents

Color Key

Abemaciclib

Abiraterone Acetate

Acalisib

Adavosertib

Ado-Trastuzumab Emtansine

Afatinib Dimaleate

Afuresertib

Alisertib

Alpelisib

Alrizomadlin

Altiratinib

AMG337

Anastrozole

Andecaliximab (GS-5745)

Anetumab Ravtansine

Anlotinib

Apalutamide

Apatinib

Atezolizumab

Avapritinib

Avelumab

Axitinib

Belinostat

Bemarituzumab

Bempegaldesleukin

Berzosertib

Bevacizumab

BI 811283

Bicalutamide

Binimetinib

Bintrafusp Alfa

BMS-936559

Brigatinib

Buparlisib

Cabozantinib

Camrelizumab

Capivasertib

Cediranib Maleate

Ceritinib

Cetuximab

Cixutumumab

Cobimetinib Fumarate

Copanlisib

Crizotinib

Dabrafenib

Dacomitinib

Dactolisib

Danvatirsen

Darolutamide

Debio-1347

Dostarlimab

Dovitinib

Durvalumab

Elacestrant

Enasidenib Mesylate

Encorafenib

Entrectinib

Enzalutamide

Erdafitinib

Erlotinib

Everolimus

Farletuzumab

Figitumumab

Foretinib.

Fulvestrant

Futibatinib

Galunisertib

Ganitumab

Gefitinib

Geldanamycin

Iniparib

Ipatasertib

Ipilimumab

Ivosidenib

Lapatinib Ditosylate

Larotrectinib

Lasofoxifene

Lenvatinib Mesylate

LGK974

Lorlatinib

Lucitanib

Lurbinectedin

Lutetium Lu 177 Dotatate

Margetuximab-cmkb

Milademetan

Miransertib

Mirvetuximab Soravtansine

MK-0752

MK-2206

Napabucasin

Navitoclax

Necitumumab

Neratinib

Nintedanib

Niraparib

Nirogacestat

Nivolumab

Obatoclax Mesylate

Olaparib

Onartuzumab

Onatasertib

Palbociclib

Panitumumab

Pazopanib Hydrochloride

Pembrolizumab

Pemigatinib

Peposertib

Pertuzumab

Pilaralisib

Pimasertib

Ponatinib Hydrochloride

Poziotinib

Pralsetinib

Prexasertib

Pyrotinib

Ramucirumab

RC48-ADC

Rebastinib

Refametinib

Regorafenib

Ribociclib

Ripretinib

Rucaparib Camsylate

Ruxolitinib Phosphate

Sacituzumab Govitecan

Sapanisertib

Selinexor

Selitrectinib

Selpercatinib

Selumetinib

Serabelisib

Sintilimab

Sonolisib

Sorafenib

Sotorasib

Spartalizumab

Sunitinib

Talazoparib Tosylate

Taletrectinib

Tamoxifen

Telaglenastat

Temsirolimus

Tepotinib

Tivantinib

Toripalimab

Trametinib

Trastuzumab

Trastuzumab deruxtecan-nxki

Tremelimumab

Tucatinib

Uprosertib

Urelumab

Vandetanib

Vanucizumab

Veliparib

Vemurafenib

Venetoclax

Vistusertib

Vopratelimab

Vorinostat

Zanidatamab

Ziv-Aflibercept

Zotatifin

Index.

Notes:

Includes index.

Description based on print version record.

ISBN:

1-9751-8457-2